Background: Colorectal cancer is one of the most commonly diagnosed cancers and leading causes of malignancy-related deaths all over the world. MicroRNAs (miRNAs) can regulate more than 60% of human genes, including tumor-stimulating, and -suppressor genes. Therefore, they can promote cancer development and affect risk of malignancy. miR-92a overexpression in CRC enhances tumor proliferation, invasion, and metastasis through downregulating different pro-apoptosis proteins including Bim. This study aimed to assess the role of plasma miR-92a as non-invasive marker in CRC patients, outline correlation between plasma miR-92a and serum Bim, and determine their correlations with clinicopathological parameters in CRC and adenoma patients. Methods: A total of 54 newly diagnosed CRC patients, 15 colonic adenoma patients, and 15 age- and sex-matched control subjects were recruited in this study. Plasma miR-92a was assayed by TaqMan qRT-PCR and serum Bim was measured by ELISA. Results: Statistically significant overexpression of serum miR-92a was observed in CRC patients as compared to adenoma and control groups (p<0.001 each) and lower serum Bim in CRC patients as compared to adenoma and control groups (p=0.001, p <0.001 respectively). The ROC curve analysis showed excellent AUC for plasma miR-92a in discriminating CRC from control (AUC=0.994), and adenoma (AUC=0.993) groups with highest diagnostic performance in discriminating CRC from controls (at cutoff 1.43, sensitivity 98.1%, specificity 93.9%), and adenoma patients (at cutoff 1.78, sensitivity 92.6%, specificity 93.3%). The diagnostic performance in discriminating early from late CRC was good (at cutoff 15, AUC=0.641, sensitivity 61.2%, specificity 80%). A significant negative correlation was evident between plasma miR-92a and serum Bim both in adenoma and CRC groups (P<0.001 for both). Higher plasma miR-92a expression (r=0.275, p=0.044) and lower serum Bim (r=-0.299, p=0.028) were found to be correlated with late CRC stages. Conclusion: Circulating miR-92a and Bim could be promising, non-invasive diagnostic and prognostic biomarkers in CRC.
Zaki, A., Fawzy, A., Akel, S., Gamal, H., & Elshimy, R. A. (2022). Evaluation of microRNA 92a Expression and Its Target Protein Bim in Colorectal Cancer. Asian Pacific Journal of Cancer Prevention, 23(2), 723-730. doi: 10.31557/APJCP.2022.23.2.723
MLA
Ahmed Zaki; Amal Fawzy; Samia Y Akel; H Gamal; Reham A A Elshimy. "Evaluation of microRNA 92a Expression and Its Target Protein Bim in Colorectal Cancer". Asian Pacific Journal of Cancer Prevention, 23, 2, 2022, 723-730. doi: 10.31557/APJCP.2022.23.2.723
HARVARD
Zaki, A., Fawzy, A., Akel, S., Gamal, H., Elshimy, R. A. (2022). 'Evaluation of microRNA 92a Expression and Its Target Protein Bim in Colorectal Cancer', Asian Pacific Journal of Cancer Prevention, 23(2), pp. 723-730. doi: 10.31557/APJCP.2022.23.2.723
VANCOUVER
Zaki, A., Fawzy, A., Akel, S., Gamal, H., Elshimy, R. A. Evaluation of microRNA 92a Expression and Its Target Protein Bim in Colorectal Cancer. Asian Pacific Journal of Cancer Prevention, 2022; 23(2): 723-730. doi: 10.31557/APJCP.2022.23.2.723
)